Netherlands Cancer Insitute
🇳🇱Netherlands
- Country
- 🇳🇱Netherlands
- Ownership
- Private
- Established
- 1913-10-10
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.nki.nl
Clinical Trials
233
Active:32
Completed:73
Trial Phases
6 Phases
Early Phase 1:2
Phase 1:46
Phase 2:61
+3 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (198 trials with phase data)• Click on a phase to view related trials
Not Applicable
61 (30.8%)Phase 2
61 (30.8%)Phase 1
46 (23.2%)Phase 3
26 (13.1%)Early Phase 1
2 (1.0%)Phase 4
2 (1.0%)Short Course of Radiotherapy Prior to Surgery of Soft Tissue Sarcomas
Not Applicable
Not yet recruiting
- Conditions
- Sarcoma of Soft TissueSarcomaSarcoma, Soft Tissue
- First Posted Date
- 2025-07-17
- Last Posted Date
- 2025-07-17
- Lead Sponsor
- The Netherlands Cancer Institute
- Target Recruit Count
- 150
- Registration Number
- NCT07071727
- Locations
- 🇳🇱
Netherlands Cancer Institute, Amsterdam, Netherlands
Cardiotoxicity and Other Late Effects After Radiotherapy and Immuno-chemoTherapy in Non-Hodgkin lYmphoma
Completed
- Conditions
- Non Hodgkin LymphomaDLBCLCardiovascular DiseasesCardiomyopathiesCardiotoxicityMetabolic SyndromeQuality of LifeLate EffectHeart Failure
- First Posted Date
- 2025-06-27
- Last Posted Date
- 2025-06-27
- Lead Sponsor
- The Netherlands Cancer Institute
- Target Recruit Count
- 217
- Registration Number
- NCT07041827
- Locations
- 🇳🇱
Netherlands Cancer Institute, Amsterdam, North Holland, Netherlands
Functional Liver After SBRT
Not yet recruiting
- Conditions
- Liver Metastases
- First Posted Date
- 2025-06-24
- Last Posted Date
- 2025-07-02
- Lead Sponsor
- The Netherlands Cancer Institute
- Target Recruit Count
- 15
- Registration Number
- NCT07033364
TAO-Towards Optimal (Neo)Adjuvant Systemic Therapy of Stage III Triple-negative Breast Cancer
Not yet recruiting
- Conditions
- Breast Cancer
- First Posted Date
- 2025-04-17
- Last Posted Date
- 2025-04-17
- Lead Sponsor
- The Netherlands Cancer Institute
- Target Recruit Count
- 100
- Registration Number
- NCT06931769
- Locations
- 🇳🇱
The Netherlands Cancer Institute, Amsterdam, Netherlands
Bevacizumab Versus Corticosteroids As First-line Treatment in Patients with Symptomatic Cerebral Radiation Necrosis After Radiation for High-grade Glioma or Brain Metastases
Phase 3
Not yet recruiting
- Conditions
- Radiation NecrosisHigh Grade Glioma (III or IV)Brain MetastasasesRadiation ToxicityRadiation EffectRadiation InjuryRadiation Injuries
- Interventions
- First Posted Date
- 2025-03-25
- Last Posted Date
- 2025-03-30
- Lead Sponsor
- The Netherlands Cancer Institute
- Target Recruit Count
- 408
- Registration Number
- NCT06888817
- Locations
- 🇳🇱
Netherlands Cancer Institute - Antoni van Leeuwenhoek, Amsterdam, Netherlands
🇳🇱Amsterdam University Medical Centers, location VUmc and AMC, Amsterdam, Netherlands
🇳🇱Leiden University Medical Center, Leiden, Netherlands
- Prev
- 1
- 2
- 3
- 4
- 5
- 44
- Next
News
No news found